La aspergilosis broncopulmonar alérgica (ABPA) es una enfermedad inflamatoria de las vías respiratorias, de origen inmunitario, que afecta principalmente a pacientes con fibrosis quística (FQ) y, con menor frecuencia, a pacientes con asma. La ABPA puede causar lesiones pulmonares irreversibles y bronquiectasias si no se trata de forma temprana y activa. Los esteroides orales a largo plazo, el tratamiento estándar para la ABPA, se asocian con un riesgo mayor de efectos secundarios y un posible incumplimiento de la medicación. Se ha utilizado un bolo mensual de metilprednisolona intravenosa (IV-PS) como alternativa a los esteroides orales para tratar la ABPA vinculada con la FQ, y se ha reportado una respuesta clínica similar y menos efectos secundarios relacionados con los esteroides. Hasta donde sabemos, no se ha reportado el uso de la IV-PS en la ABPA asociada con asma. Presentamos el tratamiento exitoso de ABPA relacionada con asma en un adolescente, utilizando un bolo de metilprednisolona intravenosa combinado con itraconazol oral, sin efectos secundarios significativos debidos a los esteroides.

Keywords:
Aspergilosis broncopulmonar alérgica (ABPA), Asma, Bolo de esteroides
This content is only available via PDF.
© 2022 The Author(s). Published by S. Karger GmbH, Freiburg
2022
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
This work is licensed under a Creative Commons Attribution 4.0 International License .
Attribution